China National Pharmaceutical Group Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: July 30, 2014
Pages: 72
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CE3B036C564EN
Leaflet:

Download PDF Leaflet

China National Pharmaceutical Group Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

China National Pharmaceutical Group Corporation (Sinopharm) is a pharmaceutical company. It manufactures and distributes psychotropic and narcotic drugs. The company’s products include anti-cancer drugs, traditional and herbal medicines, and cephalosporin injection powder, chemical raw materials, biochemical products, antibiotics, biological products, and licorice tablets. The company owns 10 wholly-owned subsidiaries and five holding companies which include one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. Sinopharm is headquartered in Haidian, Beijing, China.

China National Pharmaceutical Group Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Medical Devices Deals, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Mitsubishi Forms Joint Venture With Sinopharm
Guizhou Factorr Bio-Technology Enters Into Joint Venture Agreement With National Vaccine And Serum Institute
China NT Pharma To Form Joint Venture With Sinopharm
China State Institute of Pharma Enters Into Research Agreement With Sanofi
Refine Technology Enters Into Co-Development Agreement With Wuhan Institute of Biological Products
Aeras Enters Into Co-Development Agreement With China National Biotech Group
ImmunoBiology Enters Into Co-Development Agreement With Lanzhou Institute
Shenzhen Accord Pharma Plans To Form Joint Venture
University of Hong Kong Enters Into Research And Development Agreement With China National Pharma
GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm
Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry
Merck & Co Enters Into Co-Marketing Agreement With Sinopharm Group
Merck Sharp & Dohme Signs Letter Of Intent With Sinopharm Group
China National Biotec Enters Into Co-Development Agreement With PATH
DNAVEC Enters Into Co-Development Agreement With National Vaccine & Serum Institute
Licensing Agreements
Fina Biosolutions Enters Into Licensing Agreement With Chengdu Institute of Biological Products For Vaccine Technology
ProMetic Life Sciences Expands Licensing Agreement With Wuhan Institute
Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma
ProMetic Life Sciences Enters Into Licensing Agreement With Wuhan Institute of Biological Products
Equity Offering
Sinopharm Completes Private Placement Of Shares For US$525 Million
China National Pharma Completes IPO Of US$1.13 Billion
Debt Offering
Sinopharm Group Announces Private Placement Of Medium Term Bonds For US$466 Million
Sinopharm Group Completes Private Placement Of Medium Term Bonds For US$308 Million
Acquisition
Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For US$49 Million
Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For US$9.8 Million
Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For US$2.8 Million
Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For US$16 Million
Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med
Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For US$132.6 Million
China National Pharma Acquires 37.1% Stake In Winteam Pharma For US$32.5 Million
Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For US$3.3 Million
Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For US$6.4 Million
China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For US$5 Million
China National Accord To Acquire 70% Stake In Guangdong Pharma Company For US$2.14 Million
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma
Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang
Shenzhen Accord Pharma To Acquire 52% Stake In Sinopharm Holdings Shenzhen TCM
Shenzhen Accord Pharma Acquires 51% Stake In Shenzhen Yanfeng Medicine From Shenzhen Kaijiefeng For US$5.6 Million
Shenzhen Accord Pharma Acquires Zhanjiang Tianfeng Pharma For US$0.17 Million
Sinopharm Completes Acquisition Of China National Biotec
Mitsubishi And MEDIPAL Acquire Stake In Sinopharm Medicine Holding
Shenzhen Accord Pharma Acquires 75% Stake In Suzhou Wanqing Pharma
Beijing Tiantan Acquires 90% Stake In Chengdu Rongsheng
China National Pharmaceutical Group Corporation - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Key Facts
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Deals By Therapy Area, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Medical Devices Deals, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Mitsubishi Forms Joint Venture With Sinopharm
Guizhou Factorr Bio-Technology Enters Into Joint Venture Agreement With National Vaccine And Serum Institute
China NT Pharma To Form Joint Venture With Sinopharm
China State Institute of Pharma Enters Into Research Agreement With Sanofi
Refine Technology Enters Into Co-Development Agreement With Wuhan Institute of Biological Products
Aeras Enters Into Co-Development Agreement With China National Biotech Group
ImmunoBiology Enters Into Co-Development Agreement With Lanzhou Institute
Shenzhen Accord Pharma Plans To Form Joint Venture
University of Hong Kong Enters Into Research And Development Agreement With China National Pharma
GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm
Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry
Merck & Co Enters Into Co-Marketing Agreement With Sinopharm Group
Merck Sharp & Dohme Signs Letter Of Intent With Sinopharm Group
China National Biotec Enters Into Co-Development Agreement With PATH
DNAVEC Enters Into Co-Development Agreement With National Vaccine & Serum Institute
Fina Biosolutions Enters Into Licensing Agreement With Chengdu Institute of Biological Products For Vaccine Technology
ProMetic Life Sciences Expands Licensing Agreement With Wuhan Institute
Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma
ProMetic Life Sciences Enters Into Licensing Agreement With Wuhan Institute of Biological Products
Sinopharm Completes Private Placement Of Shares For US$525 Million
China National Pharma Completes IPO Of US$1.13 Billion
Sinopharm Group Announces Private Placement Of Medium Term Bonds For US$466 Million
Sinopharm Group Completes Private Placement Of Medium Term Bonds For US$308 Million
Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For US$49 Million
Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For US$9.8 Million
Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For US$2.8 Million
Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For US$16 Million
Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med
Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For US$132.6 Million
China National Pharma Acquires 37.1% Stake In Winteam Pharma For US$32.5 Million
Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For US$3.3 Million
Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For US$6.4 Million
China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For US$5 Million
China National Accord To Acquire 70% Stake In Guangdong Pharma Company For US$2.14 Million
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma
Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang
Shenzhen Accord Pharma To Acquire 52% Stake In Sinopharm Holdings Shenzhen TCM
Shenzhen Accord Pharma Acquires 51% Stake In Shenzhen Yanfeng Medicine From Shenzhen Kaijiefeng For US$5.6 Million
Shenzhen Accord Pharma Acquires Zhanjiang Tianfeng Pharma For US$0.17 Million
Sinopharm Completes Acquisition Of China National Biotec
Mitsubishi And MEDIPAL Acquire Stake In Sinopharm Medicine Holding
Shenzhen Accord Pharma Acquires 75% Stake In Suzhou Wanqing Pharma
Beijing Tiantan Acquires 90% Stake In Chengdu Rongsheng
China National Pharmaceutical Group Corporation, Key Competitors
China National Pharmaceutical Group Corporation, Key Employees
China National Pharmaceutical Group Corporation, Subsidiaries

LIST OF FIGURES

China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
China National Pharmaceutical Group Corporation, Medical Devices Deals, 2008 to YTD 2014
Skip to top


Ask Your Question

China National Pharmaceutical Group Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: